BFIC
LGND icon

Bedell Frazier Investment Counselling’s Ligand Pharmaceuticals LGND Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-87,061
Closed -$4.19M – 71
2015
Q1 		$4.19M Buy
+87,061
New +$3.34M 1.74% 25

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bedell Frazier Investment Counselling's LGND Position: Q2 2015 in Review

Bedell Frazier Investment Counselling sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 87,061 shares — an estimated $4.19M sold.

Bedell Frazier Investment Counselling first reported a position in LGND in Q1 2015 and held it in 1 quarter. The position peaked at $4.19M in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

  • Bedell Frazier Investment Counselling reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Bedell Frazier Investment Counselling sold 87,061 Ligand Pharmaceuticals shares in Q2 2015, an estimated $4.19M.
  • Bedell Frazier Investment Counselling first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Bedell Frazier Investment Counselling's Ligand Pharmaceuticals position peaked at $4.19M in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Bedell Frazier Investment Counselling's 13F filing for Q2 2015, filed 11 Aug 2015.